UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): April 17, 2019

 

  

ASSEMBLY BIOSCIENCES, INC.

(Exact name of registrant as specified in its charter)

 

 

Delaware		001-35005		20-8729264
(State or other jurisdiction of incorporation)		(Commission File Number)		(I.R.S. Employer Identification No.)

 

11711 N. Meridian St., Suite 310 Carmel, Indiana 46032

(Address of principal executive offices, including zip code)

 

(317) 210-9311

(Registrant’s telephone number, including area code)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

o

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

 

Emerging growth company    o

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.     o

 

 

Item 5.02    Departure of Directors or Certain Officers; Election of Directors; Compensatory Arrangements of Certain Officers.

 

(b)

 

On April 17, 2019, Assembly Biosciences, Inc. (the “Company”) and Uri A. Lopatin, M.D., its Chief Medical Officer and a named executive officer of the Company, announced that he is stepping down as Chief Medical Officer effective as of the close of business on May 6, 2019, and will transition to a clinical and scientific advisor role. Dr. Lopatin will transition his clinical development duties to the Company’s newly hired Senior Vice President, Clinical Development, Steven J. Knox. The Company has a search underway for a chief medical officer candidate to replace Dr. Lopatin. Dr. Lopatin will remain with the Company as a clinical and scientific advisor. The terms of this consulting arrangement have not been finalized.

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: April 22, 2019	Assembly Biosciences, Inc.
	By:	/s/ Derek A. Small
		Derek A. Small
		President and Chief Executive Officer